Haemonetics (HAE) PT Raised to $142 at Baird
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St set to open lower after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $116.16 --0%
Rating Summary:
11 Buy, 9 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 11 | New: 15
Rating Summary:
11 Buy, 9 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 11 | New: 15
Join SI Premium – FREE
Baird analyst David Rescott raised the price target on Haemonetics (NYSE: HAE) to $142.00 (from $119.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Brunswick Corp (BC) PT Lowered to $66 at JPMorgan
- Honeywell International (HON) PT Lowered to $269 at RBC Capital
- Celestica (CLS) PT Lowered to $400 at BMO Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
